p21 and p27: Roles in carcinogenesis and drug resistance

Abde M. Abukhdeir, Ben Ho Park

Research output: Contribution to journalReview articlepeer-review

Abstract

Human cancers arise from an imbalance of cell growth and cell death. Key proteins that govern this balance are those that mediate the cell cycle. Several different molecular effectors have been identified that tightly regulate specific phases of the cell cycle, including cyclins, cyclin-dependent kinases (CDKs) and CDK inhibitors. Notably, loss of expression or function of two G1-checkpoint CDK inhibitors - p21 (CDKN1A) and p27 (CDKN1B) - has been implicated in the genesis or progression of many human malignancies. Additionally, there is a growing body of evidence suggesting that functional loss of p21 or p27 can mediate a drug-resistance phenotype. However, reports in the literature have also suggested p21 and p27 can promote tumours, indicating a paradoxical effect. Here, we review historic and recent studies of these two CDK inhibitors, including their identification, function, importance to carcinogenesis and finally their roles in drug resistance.

Original languageEnglish (US)
JournalExpert Reviews in Molecular Medicine
Volume10
Issue number19
DOIs
StatePublished - Jul 2008

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)
  • Molecular Medicine

Fingerprint Dive into the research topics of 'p21 and p27: Roles in carcinogenesis and drug resistance'. Together they form a unique fingerprint.

Cite this